Sung Lee - 27 Mar 2024 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Reporting relationship: EVP & Chief Financial Officer
Issuer ticker: VIR
Reported as of: 27 Mar 2024
Net transaction value: -$59,404
SEC form: 4
Accepted by SEC: 28 Mar 2024, 12:18:57 UTC
Prior SEC filing: 26 Feb 2024
Next SEC filing: 30 Apr 2024
Source filing: View source filing
Reporting owner signature: /s/Sung Lee

Key filing fact

Sung Lee filed Form 4 for Vir Biotechnology, Inc. (VIR) on 28 Mar 2024.

Key facts

This page summarizes Sung Lee's Form 4 filing for Vir Biotechnology, Inc. (VIR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Mar 2024, 12:18.

Change

Previous filing in this sequence was filed on 26 Feb 2024.
Current net transaction value: -$59,404.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VIR transaction

Common Stock

Sale

Transaction value: $59,404
Shares: -6,008
Change %: -5.6%
Price: $9.89
Shares after: 100,492
Date: 27 Mar 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.